Order results by:
| Issue | Title | |
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis | Abstract similar documents |
| A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova | ||
| "... prices. The budget impact analysis of the influence of netakimab inclusion in the therapy for patients ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation | Abstract similar documents |
| S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev | ||
| "... . Budget impact analysis for the partial replacement of omalizumab with mepolizumab and/or reslizumab has ..." | ||
| Vol 12, No 2 (2019) | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... . The economic assessment was made using the cost-effectiveness analysis and budget impact analysis. The cost ..." | ||
| Vol 15, No 1 (2022) | Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation | Abstract similar documents |
| T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg | ||
| "... technology medical care list part 1 (HТMC 1). Budget impact analysis compared the costs of using ICD within ..." | ||
| Vol 14, No 2 (2021) | Clinical and economic analysis of using the thrombodynamics test in patients undergoing treatment with assisted reproductive technologies in the Russian Federation | Abstract similar documents |
| D. G. Shchurov, V. S. Dombrovskiy | ||
| "... in infertile patients undergoing treatment with assisted reproductive technologies (ART), as well as the impact ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer | Abstract similar documents |
| N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov | ||
| "... consisted of two parts: clinical and economic study and budget impact analysis. We used cost minimization ..." | ||
| Vol 15, No 3 (2022) | Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... . Objective: to perform a long-term analysis of canagliflozin budget impact in adult patients with DM2 and DN ..." | ||
| Vol 13, No 4 (2020) | Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy | Abstract similar documents |
| I. N. Dyakov, S. R. Varfolomeеva | ||
| "... -effectiveness analysis) with a sensitivity analysis; and a "budget impact" analysis with a sensitivity analysis ..." | ||
| Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
| "... parameters, budget impact analysis were carried out. Results. The total medical costs for CP/EP + ATZ course ..." | ||
| Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... ,165.00 rubles (–0.4%). The budget impact analysis showed that an increase in the proportion of patients ..." | ||
| Vol 16, No 1 (2023) | Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022 | Abstract similar documents |
| D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, M. A. Polzikov, A. S. Semikhin | ||
| "... follitropin alfa, there was a 103% increase in savings. Budget impact analysis determined that switching 25 ..." | ||
| Vol 13, No 2 (2020) | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation | Abstract similar documents |
| S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... and budget impact analyses were performed. Results. The drug costs for T+O were the lowest among all ..." | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies | Abstract similar documents |
| K. A. Perova, D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, N. Z. Musina | ||
| "... of the budget impact analysis included the costs required for the ovarian stimulation of patients distributed ..." | ||
| Vol 16, No 2 (2023) | Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination | Abstract similar documents |
| I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova | ||
| "... (treated separately), ART program cycle, relief of complications. As part of the budget impact analysis ..." | ||
| Vol 17, No 4 (2024) | Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... and budget impact analysis, with consideration to the efficacy of the compared therapeutic regimens. Data ..." | ||
| Vol 16, No 3 (2023) | Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... and third lines of NSCLC therapy. The budget impact analysis demonstrated that if all patients in the target ..." | ||
| Vol 12, No 1 (2019) | Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan | Abstract similar documents |
| T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova | ||
| "... optimization in the Republic of Tatarstan. Materials and methods. A budget impact model was created to compare ..." | ||
| Vol 15, No 2 (2022) | Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... (LAAC) with its insufficient effectiveness. Material and methods. The analysis of the impact ..." | ||
| Vol 11, No 4 (2018) | Organization and financial support of healthcare for public employees in the Russian Federation: a review of departmental health services in the Ministry of Defense | Abstract similar documents |
| D. V. Lukyantseva, L. S. Melnikova, D. V. Fedyaev, T. P. Bezdenezhnykh, V. V. Omelyanovskiy | ||
| Vol 14, No 4 (2021) | Economic outcomes of centralized procurements of gene therapy for patients with orphan diseases: inherited retinal dystrophy | Abstract similar documents |
| N. А. Avxentyev, Yu. V. Makarova, V. V. Kadyshev | ||
| "... . Budget costs of treatment were estimated for two scenarios: status-quo, where gene therapy is purchased ..." | ||
| Vol 15, No 1 (2022) | Pharmacoepidemiological analysis of medication consumption in a multidepartmental hospital as an element of medical care quality management and the basis for assessing import substitution | Abstract similar documents |
| O. V. Zhukova, O. V. Ruina, M. V. Khazov, T. M. Konyshkina, E. A. Rodin, D. K. Lipatov | ||
| "... Objective: pharmacoepidemiological analysis of medication list used in a multidepartmental ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic features of drug provision to the rheumatology department of the republican clinical hospital | Abstract similar documents |
| L. N. Sheikhmambetova, E. A. Egorova, K. N. Onishchenko, E. I. Konyaeva | ||
| "... expenditure was carried out using ABC/VEN analysis. Results. The total expenditure on the procurement ..." | ||
| Vol 16, No 4 (2023) | Investigating the current state of the Russian market for drugs treating infectious and inflammatory conditions of oral cavity and oropharynx to demonstrate the need for new drug development | Abstract PDF (Eng) similar documents |
| V. I. Zvereva, D. R. Dzhavakhyan, V. N. Dul, V. S. Bobyleva, A. A. Markaryan, E. I. Morkovin, D. V. Kurkin, M. A. Dzhavakhyan | ||
| "... . The analysis of scientific publications in the field of marketing research of drugs, found in eLibrary ..." | ||
| Vol 12, No 3 (2019) | Pharmacoepidemiological analysis of antimicrobial therapy for burn injury in the hospital settings | Abstract similar documents |
| O. V. Zhukova, E. S. Nekaeva, E. S. Khoroshavina, E. A. Kozlova, Yu. A. Dudukina, I. Yu. Arefyev | ||
| "... Aim: to conduct a pharmacoepidemiological analysis of antimicrobial therapy of burn injury ..." | ||
| Vol 16, No 2 (2023) | Pharmacoepidemiological and drug interaction analysis in the treatment of chronic renal and hepatic failure | Abstract similar documents |
| O. V. Zhukova, D. S. Fokina, O. V. Ruina, M. V. Khazov | ||
| "... Objective: to perform pharmacoepidemiological and drug interaction analysis of pharmacotherapy ..." | ||
| Vol 11, No 4 (2018) | Costs of pharmacotherapy in pediatric patients with community-acquired pneumonia: mathematical and statistical analysis | Abstract similar documents |
| I. A. Narkevich, O. D. Nemyatyh, D. D. Siukaeva, I. V. Pavlushkov, D. O. Ivanov, Ya. V. Panyutina | ||
| "... The aim of the study is to determine the limits of using the mathematical-statistical analysis ..." | ||
| Vol 17, No 2 (2024) | Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... in terms of overall survival and progression-free survival. Therefore, a cost minimization analysis method ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer | Abstract similar documents |
| O. P. Bobrova, S. K. Zyryanov, N. A. Shnayder, M. M. Petrova | ||
| "... on the analysis of its cost and effectiveness in patients with chronic pain syndrome in pancreatic cancer ..." | ||
| Vol 16, No 3 (2023) | Retrospective pharmacoeconomic study of antibiotic therapy in community-acquired pneumonia | Abstract similar documents |
| A. A. Taube, T. V. Alexandrova, O. A. Demidova, M. V. Zhuravleva | ||
| "... and plan the budget of local healthcare systems. Material and methods. A retrospective epidemiological ..." | ||
| Vol 16, No 3 (2023) | Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study | Abstract similar documents |
| A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina | ||
| "... to the equivalence of strategies regarding overall and non-progressive survival, the cost minimization analysis ..." | ||
| Vol 16, No 3 (2023) | Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... Objective: to perform a cost-effectiveness analysis of using encorafenib and binimetinib ..." | ||
| Vol 17, No 1 (2024) | STEP analysis of macro-environmental factors affecting medical and drug care for patients with chronic myeloid leukemia | Abstract similar documents |
| A. V. Zhuravlev, O. I. Knysh | ||
| "... Objective: to conduct a STEP analysis (social, technological, economic, political) of macro ..." | ||
| Vol 17, No 3 (2024) | Chemoproteomic analysis of the pharmacological properties of vitamin В12 derivatives | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, I. A. Dereven’kov, L. A. Maiorova | ||
| "... . Material and methods. Using the method of chemoinformational (chemoproteomic) analysis, implemented within ..." | ||
| Vol 17, No 3 (2024) | Chemoreactomic analysis of the antioxidant properties of vitamin B12 derivatives | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, L. A. Maiorova | ||
| "... the method of chemoreactomic analysis, implemented within the framework of the algebraic theory ..." | ||
| Vol 12, No 2 (2019) | Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers | Abstract similar documents |
| E. V. Radchenko, A. S. Kolbin | ||
| "... of life and health expectancy of smokers but also save a considerable amount of budget funds. ..." | ||
| Vol 12, No 3 (2019) | Clinical and economic analysis as an instrument for harmonizing import substitution in the preferential segment of medicinal support | Abstract similar documents |
| E. V. Eliseeva , E. S. Maneeva , R. K. Goncharova , A. V. Kropotov | ||
| "... Clinical / Economic Analysis and the common ABC / VEN analysis are currently used to estimate ..." | ||
| Vol 12, No 4 (2019) | Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis | Abstract similar documents |
| I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva | ||
| "... Aim: to conduct a comparative clinical and economic analysis of using three SYSADOA drugs ..." | ||
| Vol 13, No 4 (2020) | Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard | Abstract similar documents |
| I. Yu. Torshin, A. M. Lila, A. V. Naumov, A. Yu. Kochish, L. I. Alekseeva, E. A. Taskina, I. V. Sarvilina, A. N. Galustyan, A. N. Gromov, A. K. Khadzhidis, L. V. Vasilieva, E. F. Yevstratova, M. I. Udovika, O. A. Gromova | ||
| "... Aim. A meta-analysis of 8 controlled studies (n=771, age 53.6±6.2 years) of tie use of tie ..." | ||
| Vol 15, No 2 (2022) | Pharmacoeconomic study of the treatment of arterial hypertension in children and adolescents using cost-of-illness analysis | Abstract similar documents |
| O. S. Mikhaylova, A. V. Krikova | ||
| "... Background. The cost-of-illness (COI) analysis allows to estimate and plan costs for calculations ..." | ||
| Vol 14, No 1 (2021) | Differences in the standardization of medicinal products based on extracts of chondroitin sulfate | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, B. Ts. Zaychik, E. V. Shikh, A. O. Ruzhitskiy, A. N. Galustyan, I. S. Sardaryan, I. V. Sarvilina | ||
| "... Objective: a comparative analysis of 6 different chondroprotectors for injection, containing ..." | ||
| Vol 16, No 4 (2023) | Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| "... in the Russian Federation. Material and methods. A clinical and economic analysis of using benralizumab ..." | ||
| Vol 17, No 3 (2024) | Review of open libraries for pharmacoeconomic analysis in R environment | Abstract similar documents |
| I. A. Lackman, R. I. Sladkov, V. M. Timiryanova | ||
| "... and disease outcome, new methods of analysis and modeling are actively being developed, and tools are becoming ..." | ||
| Vol 17, No 2 (2024) | Chemoreactomic study of fonturacetam effects: molecular mechanisms of influence on adipose tissue metabolism | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin | ||
| "... learning systems in the field of postgenomic pharmacology. Analysis of pharmacological capabilities ..." | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| "... analysis (CEA) of the use of lanreotide and prolonged-release octreotide in adult patients with acromegaly ..." | ||
| Online First | Chemoreactomic analysis of the drug prototype рilim-1 in comparison with zinc derivatives of nonsteroidal anti-inflammatory drugs | Abstract similar documents |
| P. A. Galenko-Yaroshevsky, I. Y. Torshin, A. N. Gromov, I. A. Reyer, O. A. Gromova, B. A. Trofimov, L. N. Parshina, R. A. Murashko, O. V. Shelemekh, A. V. Zadorozhniy, V. L. Popkov, A. V. Zelenskaya, I. B. Nektarevskaya, A. V. Sergeeva, A. V. Uvarov, Yu. V. Tovkach, I. V. Sholl | ||
| "... , diclofenac and nimesulide) was carried out using the methods of chemoinformation analysis of molecules ..." | ||
| Online First | Clinical and economic assessment of nosocomial pneumonia antibacterial therapy in Moscow hospital | Abstract similar documents |
| D. D. Ivanova, I. N. Sychev, N. B. Lazareva | ||
| "... Objective: to conduct clinical and economic analysis of nosocomial pneumonia antibacterial therapy ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract similar documents |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| Online First | Analysis of fatty acid profiles of micronutrients and pharmaceuticals based on omega-3 polyunsaturated fatty acid extracts from natural sources | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, A. A. Garanin | ||
| Vol 17, No 2 (2024) | Clinical and economic assessment of using topical bacterial lysate Imudon® for the treatment and prevention of acute upper respiratory tract infections in children | Abstract similar documents |
| A. R. Kasimova, A. S. Kolbin | ||
| "... Objective: pharmacoeconomic analysis of the feasibility of using topical bacterial lysate Imudon ..." | ||
| Vol 12, No 1 (2019) | Prevalence survey of musculoskeletal and connective tissue disorders in the Russian Federation | Abstract similar documents |
| T. A. Oleynikova, D. N. Pozhidaeva, A. Yu. Oreshko | ||
| "... and connective tissue disorders in the Russian Federation. The analysis covers the entire country as well ..." | ||
| 1 - 50 of 87 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
